You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genetic analysis indicates the resurgence of Ebola in Liberia might be due to a survivor of the previous outbreak, the New York Times says.
In Cell this week: dynamics of protein profusion and localization, melanoma classification schemes, and more.
A new study has found that an antigen-based rapid diagnostic test for Ebola could be more reliable under certain circumstances than a recently approved RT-PCR assay for the virus.
The scientists sequenced 85 Ebola virus samples collected last year, mostly in or around the capital Conakry.
Both studies found that the virus changed more slowly over time than initially as deleterious mutations were removed.
In Nature this week: photoactivatable CRISPR/Cas9, genetic analysis of Ebola virus evolution, and more.
The Belgian MDx firm's sights are set on assays for cancer, infectious disease, and sepsis, as well as new iterations of its flagship Idylla platform.
Two teams from Europe and the US took the Oxford MinIon sequencer to West Africa to sequence Ebola samples.
Researchers used Thermo Fisher's Ion Torrent technology to generate the data, which will allow researchers to monitor the evolution of the pathogen in real time.
Researchers sequenced 25 Ebola genomes isolated from patients infected during the outbreak, publishing their results in Emerging Infectious Diseases.
The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.
According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.
The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.
In Nature this week: the largest known collection of human genetic variants, and more.